$6.00
▼ -4.6% Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating
Overview
52-week range
$4.70
$16
12% of range
Avg surprise (last 3)
-16.0%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
379%
EM ±63.3% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.38 | $-0.30 | -26.7% | -90.0% | -6.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.24 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.29 | $-0.28 | -3.6% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.20 | $-0.17 | -17.6% | — | +6.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.16 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.16 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.25 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.35 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.40 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | — | $30M | $34M | $38M | — | $35M | $35M |
| Cost of revenue | $7M | — | $6M | $8M | $10M | — | $10M | $11M |
| Gross profit | $23M | — | $24M | $25M | $28M | — | $25M | $24M |
| Operating income | $-18M | — | $-12M | $-14M | $-11M | — | $-9M | $-8M |
| Net income | $-16M | — | $-10M | $-12M | $-8M | — | $-6M | $-6M |
| EPS (diluted) | $-0.38 | — | $-0.24 | $-0.29 | $-0.20 | — | $-0.16 | $-0.16 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18M | $20M | $30M | $40M | $28M | $17M | $17M | $24M |
| Inventory | $35M | $32M | $29M | $25M | $24M | $22M | $22M | $19M |
| Total current assets | $279M | $287M | $284M | $284M | $288M | $294M | $287M | $281M |
| Total assets | $304M | $312M | $309M | $309M | $313M | $319M | $310M | $305M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $37M | $36M | $33M | $31M | $34M | $37M | $33M | $30M |
| Total equity | $267M | $276M | $276M | $278M | $279M | $281M | $277M | $275M |